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Background—We assessed vaccine effectiveness (VE) for RotaTeq (RV5; 3 doses) and Rotarix 
(RV1; 2 doses) at reducing rotavirus acute gastroenteritis (AGE) inpatient and emergency 
department (ED) visits in US children.
Methods—We enrolled children <5 years of age hospitalized or visiting the ED with AGE 
symptoms from November 2009–June 2010 and from November 2010–June 2011 at 7 medical 
institutions. Fecal specimens were tested for rotavirus by enzyme immunoassay and genotyped. 
Vaccination among laboratory-confirmed rotavirus cases was compared with rotavirus-negative 
AGE controls. Regression models calculated VE estimates for each vaccine, age, ethnicity, 
genotype, and clinical setting.
Results—RV5-specific analyses included 359 rotavirus cases and 1811 rotavirus-negative AGE 
controls. RV1-specific analyses included 60 rotavirus cases and 155 rotavirus-negative AGE 
controls. RV5 and RV1 were 84% (95% confidence interval [CI], 78%–88%) and 70% (95% CI, 
39%–86%) effective, respectively, against rotavirus-associated ED visits and hospitalizations 
combined. By clinical setting, RV5 VE against ED and inpatient rotavirus-associated visits was 
81% (95% CI, 70%–84%) and 86% (95% CI, 74%–91%), respectively. RV1 was 78% (95% CI, 
46%–91%) effective against ED rotavirus disease; study power was insufficient to evaluate 
inpatient RV1 VE. No waning of immunity was evident during the first 4 years of life for RV5, 
nor during the first 2 years of life for RV1. RV5 provided genotype-specific protection against 
each of the predominant strains (G1P[8], G2P[4], G3P[8], G12P[8]), while RV1 VE was 
statistically significant for the most common genotype, G3P[8].
Conclusions—Both RV5 and RV1 significantly protected against medically attended rotavirus 
gastroenteritis in this real-world assessment.
Keywords
rotavirus; vaccine; RotaTeq; New Vaccine Surveillance Network
Prior to rotavirus vaccine licensure in the United States, rotavirus infected nearly every US 
child early in life, accounting for up to 70% of winter hospitalizations due to acute 
gastroenteritis (AGE), with >$1 billion in healthcare and societal costs each year [1, 2]. 
Rotavirus vaccines were recommended by the US Advisory Committee on Immunization 
Practices (ACIP) [3] for routine immunization in 2006 (RotaTeq [RV5], Merck and Co, 
Whitehouse Station, New Jersey) and 2008 (Rotarix [RV1], GlaxoSmithKline Biologicals, 
Rixensart, Belgium), leading to dramatic declines in childhood rotavirus gastroenteritis [4–
8].
RV5 contains 5 reassortant rotaviruses derived from human and bovine parent strains that 
express human outer capsid proteins of 5 common circulating strains (G1, G2, G3, G4, and 
P[8]). Three oral doses of live, attenuated RV5 vaccine are administered to infants at ages 2, 
4, and 6 months. RV1 contains the live, attenuated monovalent G1P[8] human rotavirus 
strain; 2 doses of RV1 are given orally at ages 2 and 4 months. While both vaccines were 
found to be highly effective in prelicensure studies [9–12], there currently are no published 
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studies demonstrating the performance of both vaccines during routine concurrent field use 
in US childhood populations.
Using a large prospective, geographically diverse rotavirus surveillance network in the 
United States, we assessed RV5 and RV1 vaccine effectiveness (VE) in preventing rotavirus 
AGE hospitalization and emergency department (ED) visits among US children <5 years of 
age during 2 consecutive rotavirus seasons.
METHODS
Definition and Enrollment of Subjects
Details of New Vaccine Surveillance Network (NVSN) surveillance methods have been 
previously published [13–15]. Surveillance sites included Children’s Hospital and Research 
Center Oakland (Oakland, California), Seattle Children’s Hospital (Seattle, Washington), 
Children’s Mercy Hospitals and Clinics (Kansas City, Missouri), Texas Children’s Hospital 
(Houston), Cincinnati Children’s Hospital Medical Center (Cincinnati, Ohio), Vanderbilt 
University Medical Center (Nashville, Tennessee), and the University of Rochester Medical 
Center (Rochester, New York) and are hereafter referred to as “Oakland,” “Seattle,” 
“Kansas City,” “Houston,” “Cincinnati,” “Nashville,” and “Rochester.” Institutional review 
board approvals were obtained from the Centers for Disease Control and Prevention (CDC) 
and from each study site.
Children <5 years of age were enrolled if they were hospitalized or visited the ED from 1 
November 2009 through 30 June 2010 (hereafter “2010”) and from 1 November 2010 
through 30 June 2011 (hereafter “2011”) with signs of diarrhea (≥3 episodes within 24 
hours) and/or vomiting (≥1 episode within 24 hours) and had informed consent obtained 
from a parent or guardian. Children were ineligible if they had a history of immune 
deficiency, were previously enrolled for the same AGE episode within 3 days, or were 
transferred from another hospital. Children enrolled in the ED but subsequently hospitalized 
for the illness were categorized as inpatients. Race and ethnicity were reported by the child’s 
parent or guardian. Oakland participated during the 2011 season and the 6 other surveillance 
sites participated during both 2010 and 2011 seasons.
Data Collection and Laboratory Testing
Demographic and clinical information were collected for each enrolled child. Fecal samples 
were obtained within 14 days of symptom onset, with >95% of specimens obtained within 7 
days. Testing for rotavirus was performed using the commercial enzyme immunoassay 
(EIA) Rotaclone (Meridian Bioscience, Inc) at each surveillance site. Rotavirus strains were 
characterized by genotyping using reverse transcription polymerase chain reaction (RT-
PCR) and nucleotide sequencing at the CDC [16–19]. EIA-negative results with negative 
PCR results were confirmed as rotavirus negative in our analytical dataset.
Cases and Controls
Cases were children hospitalized or visiting the ED with AGE symptoms whose fecal 
specimens tested positive for rotavirus. The primary control group included children with 
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AGE whose fecal specimens tested negative for rotavirus (“rotavirus-negative AGE 
controls”).
Vaccine Effectiveness Analyses
Demographic and socioeconomic data for cases and control groups were compared by using 
Wilcoxon rank-sum tests for continuous variables and χ2 tests for categorical variables.
VE for the prevention of rotavirus-associated inpatient admissions and ED visits during 2 
rotavirus seasons, 2010 and 2011, were independently assessed for RV5 and RV1. Rotavirus 
immunization status was verified by contacting the subjects’ primary care providers and 
through regional immunization information systems. Vaccine doses were defined as valid if 
given ≥14 days before onset of symptoms for the cases and rotavirus-negative AGE 
controls. Additionally, to ensure vaccine age eligibility following licensure, subjects were 
required to be born on or after 1 April 2006 for RV5 analyses and on or after 1 August 2008 
for RV1 analyses. Finally, we restricted analyses to children who had reached the ACIP-
recommended age for completion of the vaccine series to avoid residual confounding by age 
at the time of last dose (ie, >8 months of age) [3].
The adjusted odds ratios and 95% confidence intervals (CIs) were calculated by logistic 
regression and were adjusted for month/year of birth, month/year of symptom onset, and 
surveillance site. VE was calculated using the following formula: [VE = (1 − odds ratio) × 
100]. All tests were 2-sided and P values <.05 were considered significant.
In addition to the primary VE analysis for RV5 and RV1 in concurrent use, we evaluated VE 
by vaccine dose number, season, clinical setting, age, predominant rotavirus genotype, and 
ethnicity. Subjects recorded as having 3 RV1 doses (representing <1% of RV1-vaccinated 
subjects), or those having mixed doses of both RV5 and RV1 (representing approximately 
5% of vaccinated subjects) were excluded from our analyses. Owing to low RV1 vaccine 
coverage (<5%) in Houston, Seattle, and Nashville, these 3 surveillance sites were not 
included in RV1 analyses.
Alternate Models
We conducted an alternate analysis whereby we restricted RV5 VE estimates to the same 4 
surveillance sites having RV1 vaccine coverage ≥5%, with little difference in results from 
those which we describe (data not presented). Additionally, we adjusted our data for 
insurance status and clinical setting, which modified the final estimates for both vaccines by 
0%–2% (data not presented). Lastly, we conducted conditional logistic regression models in 
which rotavirus cases were matched to rotavirus-negative AGE controls based on ±30 days 
of date of birth, and ±30 days of date of symptom onset.
RESULTS
Characteristics of Cases and Controls
RV5-specific VE analyses included 359 rotavirus cases and 1811 rotavirus-negative AGE 
controls (Figure 1A). RV1-specific VE analyses included 60 rotavirus cases and 155 
rotavirus-negative AGE controls (Figure 1B).
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The median ages of cases in both the RV5 and RV1 groups were older than the respective 
rotavirus-negative AGE controls (P < .001; Table 1). For the RV5 analyses, statistically 
significant differences between cases and rotavirus-negative AGE controls were observed by 
age, clinical setting, season, and NVSN surveillance site. For the RV1 analysis, differences 
between cases and rotavirus-negative AGE controls were seen only by season (Table 1).
Rotavirus Vaccine Effectiveness
Over the study period, the VE for ≥1 dose of any rotavirus vaccine was 80% (95% CI, 74%–
85%) against rotavirus hospitalizations and ED visits. A complete 3-dose course of RV5 
demonstrated a VE of 84% (95% CI, 78%–88%) and a complete 2-dose course of RV1 had a 
VE of 70% (95% CI, 39%–86%) in preventing rotavirus-associated hospitalizations and ED 
visits over the study period (Table 2). For those receiving less than the complete course of 
RV5, the VE estimates were 70% (95% CI, 50%–82%) for 1 dose and 78% (95% CI, 65%–
86%) for 2 doses, respectively. The single-dose RV1 VE estimate was not statistically 
significant (57% [95% CI, −45% to 87%]; Table 2).
Similar VE for RV5 was observed during each of the 2010 and 2011 seasons, with VE 
estimates of 82% (95% CI, 69%–89%) and 84% (95% CI, 77%–89%), respectively. 
Comparison across both years for RV1 was not possible, since RV1 coverage was too low to 
generate a VE estimate for 2010. VE for RV1 in 2011 was 64% (95% CI, 23%–83%; Table 
2).
Vaccine Effectiveness Against Rotavirus-Associated Hospitalization and ED Visits
RV5 vaccination was 86% (95% CI, 74%–91%) effective in preventing hospitalizations due 
to rotavirus. Inpatient RV1 VE was 32% (95% CI, −156% to 82%), a statistically 
nonsignificant result based on 22 cases and with wide confidence intervals. However, RV5 
and RV1 vaccines were similarly effective in preventing rotavirus-associated ED visits (81% 
[95% CI, 70%–84%], and 78% [95% CI, 46%–91%], respectively; Table 2).
Stratified Analyses of Vaccine Effectiveness Against Rotavirus-Associated Hospitalization 
and ED Visits
Through the fourth year of life, RV5 vaccination demonstrated statistically significant 
effectiveness in preventing rotavirus hospitalizations and ED visits. VE estimates for the 
first, second, third, and fourth year of life were 85% (95% CI, 63%–94%), 89% (95% CI, 
82%–93%), 83% (95% CI, 69%–90%), and 79% (95% CI, 56%–90%), respectively. RV1 
VE was significant for the second year of life (86% [95% CI, 60%–95%]), but not for the 
first year (56% [95% CI, −59% to 100%]); VE for the first year was again based on only 7 
cases, resulting in wide confidence intervals (Table 2).
The genotype-specific RV5 VE estimates against our 4 predominant circulating rotavirus 
strains were 89% (95% CI, 41%–98%) for G1P[8]; 87% (95% CI, 77%–93%) for G2P[4]; 
87% (95% CI, 81%–91%) for our most common strain, G3P[8]; and 83% (95% CI, 57%–
93%) for G12P[8], a previously uncommon strain (Figure 2). RV1 had a significant VE for 
our most common genotype, G3P[8] (74% [CI, 40%–89%]; Figure 2).
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We found no clear difference in VE by subject ethnicity. RV5 VE for Hispanic and non-
Hispanic subjects was 85% (95% CI, 76%–90%) and 83% (95% CI, 75%–88%), 
respectively. Protection afforded by RV1 was statistically significant for non-Hispanic 
subjects (76% [95% CI, 44%–90%]).
Alternate Analyses
Results from our matched analyses in the inpatient and ED clinical settings without age 
restrictions were comparable to those adjusted analyses presented as our principal model. In 
that matched analysis for RV5, with 400 rotavirus cases and 1800 AGE test-negative 
controls, we found a 3-dose VE of 85% (95% CI, 79%–89%). For the 2-dose course of RV1 
(74 cases matched to 255 AGE test-negative controls), the matched analysis VE was 68% 
(95% CI, 34%–85%).
CONCLUSIONS
In this geographically-diverse “real-world” assessment of concurrent RV5 and RV1 
rotavirus vaccine field performance, we found that the administration of complete courses of 
RV5 or RV1 was associated with protection against medically attended rotavirus infections 
over our study period, with VE of 84% (95% CI, 78%–88%) and 70% (95% CI, 39%–86%), 
respectively. Although VE point estimates differed between vaccines, confidence intervals 
overlapped, suggesting no statistical difference in vaccine performance. No waning of 
immunity was evident during the first 4 years of life for RV5-immunized children, nor was 
it observed during the first 2 years of life for RV1-immunized children. Both a single dose 
and 2 doses of RV5 were statistically effective; the single dose estimate for RV1 was not 
statistically significant. RV5 provided statistically significant genotype-specific protection 
against each of the 4 major circulating rotavirus strains (G1P[8], G2P[4], G3P[8], G12P[8]), 
and RV1 had a statistically significant VE for the most common genotype, G3P[8]. We 
provide the first data indicating high effectiveness of RV5 against rotavirus caused by the 
G12 genotype, a strain that was previously uncommon but has emerged over the past 
decade. Despite much higher rotavirus positive caseloads in 2011, RV5 VE was sustained 
across the full study period; study power limitations allowed a season-specific RV1 estimate 
for only 2011.
Our VE estimate for a complete course of RV5 against rotavirus-associated hospitalizations 
and ED visits was comparable to those published previously for US children. Using similar 
models, RV5-specific VE calculated by Staat et al was 88% (95% CI, 47%–97%) during the 
period 2007–2009 [20], and in 2 studies by Boom et al, RV5 VE was 89% (95% CI, 70%–
96%) in 2008 [21] and was 80% (95% CI, 45%–93%) in 2009 [22]. A VE assessment using 
medical institutions and immunization information systems for 3 states participating in the 
Emerging Infections Program Network by Cortese et al reported a complete-course RV5 VE 
of 89% (CI, 81%–94%) during the period 2007–2009 [23] among children aged 8 months or 
older. Our findings extend beyond previous work by demonstrating sustained RV5 VE for 
the first 4 years of life, which is reassuring regarding the long-term impact of the vaccine 
program.
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To our knowledge, we report the first estimates of postlicensure RV1 VE among US 
children. In the ED setting, both RV5 and RV1 vaccines performed with similar 
effectiveness (81% [95% CI, 70%–84%] and 78% [95% CI, 46%–91%], respectively), 
which is encouraging as approximately two-thirds of our rotavirus-positive cases sought care 
in an ED, and it is in this clinical setting that rotavirus has a large burden of disease upon US 
medical care [13]. However, our estimate of RV1 VE did not achieve statistical significance 
in the inpatient setting, at least partially due to sample size and the relatively low uptake of 
RV1 in the communities under surveillance, which diminished our study power. The 
epidemiologic meaning of our lower RV1 inpatient VE estimate is unclear, as large clinical 
trials in inpatient settings in several high-income countries have consistently found RV1 to 
have high efficacy [10, 12]. Further investigation of the inpatient subjects in our RV1 
analyses revealed that 4 (18%) were premature infants (half of these received complete RV1 
vaccinations) and averaged 18.3 months of age at hospitalization. These 4 children spent an 
average 3.4 days as inpatients, and none were admitted to the intensive care unit. Genotypes 
G3P[8], G2P[4], G12P[6], and G12P[8] were detected in these RV1 inpatient specimens. 
Similar VE point estimates were observed between 1 dose of RV5 and a full course of RV1, 
although our RV1 data alone are insufficient to suggest changes to dose recommendations 
for rotavirus vaccines.
Our VE estimates of RV5 and RV1 are consistent with those reported from postlicensure 
evaluations in other high-income countries. In Queensland, Australia, where RV5 coverage 
was 73% for 3 doses, this vaccine was 89%–94% effective in preventing rotavirus 
hospitalizations [24]. In Israel, where both RV5 and RV1 were licensed in 2007, children 
receiving ≥1 dose of either rotavirus vaccine had a VE of 89% (95% CI, 52%–98%) against 
rotavirus hospitalizations [25]. In Spain, where both RV5 and RV1 have been available 
since 2006, Castilla et al estimated VE against rotavirus-associated hospitalizations for a 
complete course of RV5 (81% [95% CI, 68%–89%]) and RV1 (75% [95% CI, 60%–85%]) 
[26].
Limitations to our study exist. First, RV1 was introduced to the United States in 2008 and, 
by the time of our assessment, sample sizes for the RV1-vaccinated population remained 
relatively small. Further evaluation of RV1 performance, particularly among infants and 
older children, is warranted by our results. Second, unvaccinated controls may be selectively 
less representative of the source population of cases as the proportion of overall rotavirus 
vaccine coverage increases. We did not find significant differences between cases and 
rotavirus-negative AGE controls by major factors, such as race, ethnicity, and insurance 
status, which—if present—would have potentially introduced bias as these factors might 
affect the likelihood of hospitalizations or ED visits. Typically, one could expect younger 
children to be more likely to be hospitalized. Our study design minimized these potential 
biases by using controls that were sampled from the same clinical settings and had 
characteristics observed to be similar to our case subjects. However, we did note age 
differences between cases and controls and employed several epidemiologic methods to 
reduce this potential confounding; we restricted eligible subjects to those 2 months older 
than the date of their last possible ACIP-approved dose, adjusted for year and month of birth 
in our regression analyses, stratified the VE results by age group, and saw no discernible 
differences in VE estimates when applying an alternate matched model. We note that 
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indirect protective effects from rotavirus vaccination have been suggested in observational 
studies among US children, including among the population we studied [8], and our 
estimates could potentially be affected by indirect protective effects among unimmunized 
children. Finally, we believe it is unlikely that differences in inpatient enrollment practices 
inherent to individual medical institutions influenced our results, because our RV5 findings 
are consistent with previous estimates from Cincinnati, Nashville, Rochester, and Houston 
surveillance sites using similar methodologies [21–23].
In conclusion, our assessment of a diverse sample of US children <5 years of age subject to 
“real-world” conditions found significant VE for complete courses of both RV5 and RV1 
rotavirus vaccines. No indication of waning over time was observed at the detectable limits 
for either vaccine, nor was there any significant difference in vaccine performance by 
predominant circulating strains, including the G12 genotype, which is not homotypically 
covered by these vaccines. Each of these rotavirus vaccines in concurrent use performed 
well in preventing medically attended rotavirus AGE among young children in the United 
States.
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A, RV5 analysis subject inclusion flowchart. B, RV1 analysis subject inclusion flowchart. 
Abbreviations: AGE, acute gastroenteritis; ED, emergency department; RV1, Rotarix; RV5, 
RotaTeq.
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Vaccine effectiveness and 95% confidence intervals by predominant rotavirus genotype, for 
RV5 (blue) and RV1 (yellow). Abbreviations: RV1, Rotarix; RV5, RotaTeq.
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Table 2
Stratified Vaccine Effectiveness and 95% Confidence Intervals for RV5 and RV1, Using the Rotavirus-
Negative Acute Gastroenteritis Control Group
Stratum
RV5 RV1
Cases/Controls VE (95% CI)
a Cases/Controls VE (95% CI)
a
Dose No.
 Dose 1 233/537 70% (50%–82%) 46/83 57% (−45% to 87%)
 Dose 2 239/638 78% (65%–86%) 56/140 70% (39% to 86%)
 Dose 3 307/1445 84% (78%–88%) NA NA
Season
 2010 (% fully vaccinated) 111/924 (23%/53%) 82% (69%–89%) 7/59 (0%/46%) Φ
 2011 (% fully vaccinated) 248/887 (29%/62%) 84% (77%–89%) 53/96 (26%/47%) 64% (23%–83%)
Clinical setting
 Inpatient 130/372 86% (74%–91%) 22/34 32% (−156% to 82%)
 ED 229/1439 81% (70%–84%) 38/121 78% (46%–91%)
Age
 1 y 34/402 85% (63%–94%) 7/54 56% (−59% to 100%)
 2 y 121/681 89% (82%–93%) 46/79 86% (60%–95%)
 3 y 91/414 83% (69%–90%) 7/22 Φ
 4 y 86/231 79% (56%–90%) 0/0 Φ
Predominant genotype
 G1P[8] 15/NA 89% (41%–98%) 1/NA Φ
 G2P[4] 82/NA 87% (77%–93%) 7/NA Φ
 G3P[8] 196/NA 87% (81%–91%) 44/NA 74% (40%–89%)
 G12P[8] 36/NA 83% (57%–93%) 4/NA Φ
Ethnicity
 Hispanic 160/908 85% (76%–90%) 12/30 59% (−100% to 91%)
 Non-Hispanic 199/902 83% (75%–88%) 48/125 76% (44%–90%)
Abbreviations: CI, confidence interval; ED, emergency department; NA, not applicable; RV1, Rotarix; RV5, RotaTeq; VE, vaccine effectiveness.
Φ = Insufficient RV1 coverage/subjects (see text).
a
Exact odds ratio and 95% CI.
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